BEHAVE!

One of Junkermann's most significant investments that leans into the realm of Transhumanism is Alto Neuroscience, which links Junkermann to two very substantial players: Etkin and Angermayer.

Nicole Junkermann’s NJF Capital wasn’t only invested in companies with Thiel, Epstein, Blatter and Barak. One of her most significant investments that leans into the realm of Transhumanism is Alto Neuroscience, which links Junkermann to two very substantial players: Amit Etkin and Christian Angermayer.

Through John Brockman’s Edge Foundation, Jeffrey Epstein and his colleagues not only sought to design the Technocratic world of tomorrow, but also to change the very nature and essence of humanity itself at a cellular level. In 2009, Epstein, Brockman and Musk co-hosted the Edge Master Class in Synthetic Genomics at SpaceX with two of the leading researchers in the field, J Craig Venter and George Church. Since then, the world has changed.

The COVID-19 affair has brought to the fore a range of new biomedical technologies which promise unrivalled benefits. New biotech solutions, such as mRNA technology, do not resemble the old pharmaceutical world, and the change we are experiencing is similar to previous biomedical revolutions. Humans power medical revolutions in more ways than one, and without the normalisation of mass human experimentation, advances will happen slowly. Many people will advocate for the slow and careful development of such technologies; however, as I’ve reported in Musk & Epstein: SpaceX Offenders, the lead scientists in fields such as Synthetic Genomics are very keen to advance their science with little to no safeguards.

Musk and Epstein: SpaceX Offenders

As Big Pharma races to create Humans 2.0, the question of consent has become secondary. As we see from the aftermath of the COVID debacle, there is no real accountability for the dangerous actions of those in power. In reality, the people who cover up lab leaks tend to receive promotions rather than punishment. As we have experienced with AZT, a genocide of homosexual people is acceptable, and, as a reward for managing the negative PR, Anthony Fauci received a promotion. As we learnt from the Foot and Mouth outbreak in the United Kingdom, those who ignore the science and mop up after lab leaks at Porton Down, people such as Roy Anderson and Neil Ferguson, receive awards and promotions. It’s not even veiled anymore. It’s a clear trend:

Lab Leak – Cover-up – Promotion.

While this dynamic remains in place, the most evil people in the world of Biopharma Big Tech remain the biggest and most significant risks to the continuation of Humans 1.0.

Porton Down's Ideological Cloud

Is it a surprise that those who should be the most accountable are the least accountable? It is another running theme in our current lived reality: those who are meant to be the most holy are the most evil, those who should be in positions of trust are the least trustworthy, and those who are given the keys to the kingdom are more often than not, the enemy of the people.

One of the companies examined in this article promises to integrate:

“…the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today’s trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.”

It is clearly hubris to believe that the present “trial-and-error clinical approach” is the issue. It isn’t only a mechanism to ensure slow, careful testing for safety and efficacy; it’s a way to test the product’s value not only to customers but also to investors. Instead, companies can now make promises they have no intention of keeping because they feel fundamentally protected from criminal prosecution. By skipping and belittling standard testing and safeguarding protocols, companies such as Alto Neuroscience not only endanger millions of lives but also commit a critical business error. If the quality, effectiveness, and efficacy of the actual products biotechnology companies offer are not adequately tested, the sales pitch to investors becomes just a process of pushing unproven overpromises. It becomes like marketing rather than science.

I began investigating Alto Neuroscience as an extension of my research into the associate of Jeffrey Epstein, Nicole Junkermann. Countess Brachetti Peretti, as she’s also known, has significant investments in companies integral to both the Technocratic and Transhumanist agendas. Junkermann’s investments alongside Peter Thiel, Jeffrey Epstein, Ehud Barak, and Elon Musk in companies such as the dystopian Mossad-linked enterprise Carbyne911 and SpaceX, along with some of her previous questionable associations and actions, raise more questions than answers. It is for this reason that Alto Neuroscience requires extra scrutiny.

Nicole Junkermann has obtained five interim injunctions against my previous reporting on her links to Jeffrey Epstein since 2019. These blatant acts of strategic litigation are not possible in most Western countries. However, Junkermann has obtained these injunctions via a Berlin regional court. She has used those injunctions to prevent my reporting on her from reaching a German audience. This is my first article investigating Nicole Junkermann’s German links.

Alto Neuroscience, Etkin and Angermayer

Alto Neuroscience isn’t simply a “clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform”. The Los Altos company, founded by Amit Etkin, Dan Segal, and Wei Wu in 2019, has received strong backing from people with serious connections. During the Series B funding round, Nicole Junkermann’s NJF Capital became a key investor. In the same year that Alto Neuroscience was founded, I first revealed Junkermann’s significant investment and ties to Jeffrey Epstein, Peter Thiel and former Israeli Prime Minister Ehud Barak through Carbyne911. Since then, I have closely followed Junkermann’s investments, and Alto Neuroscience is one of the most notable companies to be added to her ever-growing business portfolio.

One of the most prominent players involved in Alto Neuroscience is Amir Etkin. As with Junkermann’s business associate, Peter Thiel, Etkin started his influential career at Stanford University, as reported in a Yahoo Finance article, which states:

“Alto’s platform evolved out of more than a decade of clinical neuroscience research from the distinguished Etkin Lab at Stanford University and has since been validated by numerous publications in high-impact, peer-reviewed academic journals. This work was also recognized by the National Institutes of Health through the prestigious Director’s Pioneer Award received by Dr. Etkin, the first to be awarded in clinical psychiatry. Recognizing the therapeutic potential of these findings, Dr. Etkin is departing a tenured professorship at Stanford to continue leading Alto with the goal of revolutionizing the diagnosis and treatment of mental health conditions.”

Regardless of the therapeutic potential of Etkin’s discoveries, the road to newly designed medical alternatives is paved with human experimentation. As of the 1st December 2025, Alto Neuroscience faces a federal securities class action alleging it “misled investors about the efficacy and prospects of its drug candidate ALTO-100 and the company’s financial outlook, causing investor losses when adverse facts emerged.”

Etkin’s company faces the prospect of ruin if the class action lawsuit is successful, and it isn’t only Nicole Junkermann’s NJF Capital which is invested in Alto Neuroscience. Some of the lead investors include pharmaceutical giants like Franklin Templeton, Gaingels, Valor Equity Partners, Eli Lilly, Wellcome Trust, which helped raise $301 million during 12 rounds of funding.

The Proximal Origin of Covid Control - Redux

Etkin Labs are looking to change how mental illness is treated, and the science of behavioural change is of great interest to many influential players. Tyrannical governments would love an effective way to manipulate the behaviour of an unsettled populace, and intelligence agencies have historically been obsessed with techniques to control human behaviour. The science of behavioural change goes hand in hand with the long-practised science of psychological control and manipulation. In fact, Elon Musk, Jeff Bezos, and representatives of Thiel, were trained in 2008 via a Jeffrey Epstein-funded Edge Foundation Masterclass in behaviour modification by Richard Thaler, whose “nudge theory” was soon after studied and implemented by Western governments.

Musk & Epstein: The Third Culture Dossier

Amit Etkin claimed Alto Neuroscience would lead to a paradigm shift in mental health treatment, stating:

“For years, I personally witnessed the limitations of existing mental health treatments and lack of innovation in the space when caring for my own patients,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “Our precision psychiatry platform enables us, for the first time, to take differences in an individual’s biology into consideration to identify the right treatment from those we are developing. We believe this paradigm shift will allow us to move away from the trial-and-error approach that pervades clinical care today.” Dr. Etkin continued, “Our ultimate vision is to take the guesswork out of treating mental health conditions to dramatically improve people’s lives.”

Alto Neuroscience produced six key products, which became central to their sales pitch. The company advertises the use of compounds such as NSI-189 and agomelatine, as well as combination drug strategies, to target neurological pathways. They claim that their drugs are designed to focus on “precision approaches for depression and cognitive impairment”.

The products which Alto Neuroscience produces, which they claim have significant potential, include:

• ALTO-100: An oral small-molecule drug candidate aimed at enhancing neural plasticity in the hippocampus to treat bipolar depression.

• ALTO-300: A small molecule melatonergic agonist and serotonergic antagonist developed as an adjunctive treatment for major depressive disorder (MDD).

• ALTO-207: A fixed-dose combination of pramipexole and ondansetron designed to treat treatment-resistant depression (TRD) by enabling rapid titration and higher dosing.

• ALTO-203: An oral small molecule histamine H3 receptor inverse agonist targeting major depressive disorder patients with high levels of anhedonia.

• ALTO-101: A transdermal phosphodiesterase 4 (PDE4) inhibitor designed to improve cognitive impairment in schizophrenia patients.

• ALTO-202: An oral negative allosteric modulator of the GluN2B subunit of the NMDA receptor developed for major depressive disorder.

The German Contingent

In 2021, NJF Capitol invested in Alto Neuroscience, with reports at the time talking about another German-born investor in the company:

“Over $40 million in capital raised, including a $32 million Series A investment led by Apeiron Investment Group with participation from leading investors.”

Apeiron Investment Group is a Malta-based company that owns shares in various publicly traded firms in the US, Germany, Australia, and Canada. It is led by Christian Angermayer, who invests in fintech, life sciences, Artificial Intelligence, psychedelics and cryptocurrencies.

Christian Angermayer made his initial fortune by 2009, after co-founding a biotech firm called Ribopharma alongside his college professor. Ribopharma proclaimed itself to be “The World’s First siRNA Company,” creating innovative drugs based on RNA interference. Nowadays, Angermayer has an estimated net worth of $1.2 billion and, as I write this article, is ranked #2869 on Forbes World’s Real-Time Billionaires list.

In 2018, the year before Alto Neuroscience was founded, Angermayer founded Atai Life Sciences in Berlin, Germany. In 2025, Atai Life Sciences merged with Beckley/Psytech, forming AtaiBeckley. Although both organisations are clinical-stage biopharmaceutical companies developing potential treatments for mental health disorders, AtaiBeckley is focused on psychedelic-based neuroplastogens for rapid-acting therapy. In contrast, Alto Neuroscience is focused on precision psychiatry using biomarkers and AI to personalise treatments. In business speak, Atai’s strategy involves a decentralised platform with acquisitions, whereas Alto focuses on internal biomarker-driven development.

Angermayer’s two key biotech companies were previously based in different countries, with Atai based in Germany and Alto based in the United States. However, at the end of 2025, Christian Angermayer announced that AtaiBeckley were relocating to the US, too: “Just in time for the New Year, AtaiBeckley has become a U.S.-domiciled company—a key prerequisite for inclusion in major equity indices.”

On 30 December 2025, the AtaiBeckley website put out a press released about its redomiciliation to the United States. However, the press release came with an excessive disclaimer, which may be a result of the class action which has been levelled against Angermayer’s other biotech company, Alto Neuroscience. The disclaimer states, “Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected”.

Angermayer’s holdings also include Cryptology, which is a blockchain holding company with co-investor Mike Novogratz. The Forbes list ranks Mike Novogratz at #772, with a $5.3 billion fortune. There are some significant connections to mention regarding Mike Novogratz. The son of an award-winning West Point football lineman, Mike Novogratz studied Economics at Princeton, graduating in 1987, a year after Jeff Bezos. Novogratz began his career at Goldman Sachs around the same time as the Canadian Prime Minister Mark Carney started working for the same company. Novogratz was elected as a partner at Goldman Sachs in the same year as the collapse of the highly leveraged hedge fund Long-Term Capital Management (LTCM). The bank’s focus during this period was to withdraw as much equity as possible from the failing Russian economy, a move that pre-empted Russia’s financial collapse in August 1998 and helped limit Goldman Sachs’ losses. Mark Carney worked for Goldman Sachs directly on that project alongside the former US President George H W Bush.

Like Mark Carney, Mike Novogratz has various financial links to Canada, where his Galaxy Digital Holdings crypto investment firm is based on the Toronto Stock Exchange. Also of note, his sister, Jacqueline Novogratz, founded Acumen Fund, Inc, which is described as “an American non-profit impact investment fund that focuses on investing in social enterprises”. Acumen was founded in 2001 with seed capital from the Rockefeller Foundation and Cisco Systems and has since created partnerships with the Sapling Foundation through the Clinton Global Initiative, as well as received funds from the Bill and Melinda Gates Foundation and the Soros Economic Development Fund, to name a few.

The Race to Transhumanism

Nicole Junkermann (Countess Brachetti Peretti) and Christian Angermayer have more than their German nationality and investment in Alto Neuroscience in common. They also both have connections to Peter Thiel and the sports industry. Junkermann invested in Carbyne911 with Peter Thiel, Jeffrey Epstein and Ehud Barak, even serving on the board alongside the former head of the Israeli Defense Forces Unit 8200 Cybersecurity Division, Pinchas Buchris. Whereas Angermayer is, as Fortune Magazine put it, “best known for cofounding a steroid-enhanced version of the Olympics backed by Peter Thiel.”

In another Fortune article from July 2024 entitled “The German billionaire behind the ‘Olympics on steroids’ is a dinosaur egg-collecting film producer who takes mushroom trips twice a year,” the so-called “Enhanced Games” is described in more detail. The article explains how Angermayer and Thiel are “plotting” to create the chemically enhanced version of the Olympic Games, stating:

“The Enhanced Games is setting itself up as a rival to the Olympics with a twist. Athletes will be permitted to use select performance-enhancing drugs, including steroids, with the chance to earn a $1 million payday if they break “significant” world records. Angermayer co-founded the Enhanced Games with Aron D’Souza, with the aim of safely introducing these drugs into high-level competition. Notorious investor Thiel has been the poster boy for the games as an early backer. Three-time Olympic swimming medallist James Magnussen emerged in February as an athlete interested in competing in the games, with others allegedly in the pipeline. The group is looking to raise $300 million for the games, with Angermayer saying he has courted sovereign wealth funds as part of this drive.”

The World Anti-Doping Agency (WADA) condemned Angermayer and Thiel’s Enhanced Games as a “dangerous and irresponsible concept.”

As I reported in the article “The Epstein Associate Nobody’s Talking About,” Nicole Junkermann began her investment career in sports companies such as Winamax and Infront Sports and Media AG. Junkermann’s latter company, Infront Sports and Media, also caused controversy by utilising nepotism to secure extremely lucrative television rights for FIFA World Cup matches.

This was during a period when Junkermann began to associate with Jeffrey Epstein. As I reported in 2019:

“In 2002, Junkermann acquired the rights for the 2006 FIFA World Cup in Germany with her relatively new company Infront Sports and Media. The company was best known at this time for its president and chief executive, Philippe Blatter, the nephew of Sepp Blatter, the then-president of FIFA. This overt corrupt nepotism left Junkermann’s Infront Sports and Media as the company to market the TV rights to future major FIFA tournaments. The company went on to acquire the rights to all of FIFA’s World Cups. Although this deal was watered down in 2006, FIFA granted Infront permission again in 2011 to sell the TV rights in the Asian markets for the 2018 and 2022 World Cups. During her time at Infront Sports and Media, Junkermann flew on Jeffrey Epstein’s “Lolita Express” on three occasions.”

Historically, Angermayer, Thiel, and Junkermann have used investments in sports technology to disrupt. FIFA (Federation Internationale de Football Association) and the IOC (International Olympic Committee) are both governing bodies which have been accused of significant acts of corruption. Both FIFA and the IOC are based in Switzerland for a reason. By basing themselves in Switzerland, the organisations can avoid significant scrutiny or accountability, especially in relation to financial deals. In the same way, Angemayer’s Apeiron receives tax benefits that reduce its rates to between 5% and 10% on trading and investment income. The company’s dividends and capital gains from significant shareholdings in subsidiaries are fully tax exempt. At the same time, there is also no withholding tax on outbound dividends, interest, or royalties paid to non-residents. Malta is also progressive on digital assets, making it a great place to base a company for crypto and fintech investments.

In reality, tax havens such as Switzerland and Malta have very similar, if not indistinguishable, financial regulations to those of the planned Technocratic Megacities of the near future. Legal infrastructure and regulatory bodies will vary from city to city. Different Megacities in a single country will offer divergent and competing tax rates and regulations to encourage the redomiciliation of companies. This will also maintain a significant level of cronyism and corruption, something which we already see within international governing bodies, Big Tech enterprises, financial institutions and meritocratic organisations more generally.

The Behavioural Baseline

While investigating the people invested in Alto Neuroscience, AtaiBeckley, and Carbyne911, and the society they want to create, one word has come up time and time again: “behaviour”.

Essentially, these organisations are on the front line of behavioural manipulation. Whether or not their experimental biopharmaceuticals can help people overcome depression or anxiety, the aim of those people evangelising this hazardous and powerful technology is not to bring comfort, but rather, to gain control. The society that Christian Angermayer and Peter Thiel want to create doesn’t rely on the success of Alto Neurosciences experimental therapies; it depends on disruption and change. They are essentially change agents. This is true of Junkermann, Epstein and many other intelligence-linked investors. It doesn’t matter whether ALTO-100 enhances neural plasticity in the hippocampus to treat bipolar depression; all that matters is that they normalise human experimentation and people’s willingness to take drugs which are supposed to enhance humans in some way.

As I reported in Musk & Epstein: The Third Culture, the heads of the biggest social media companies were trained via an Epstein-funded six-part Edge Masterclasses specifically on behavioural manipulation. Richard Thaler’s science of “nudge theory” wasn’t only marvelled over by Jeffrey Epstein and John Brockman’s Edge alumni, but it was implemented into a government department in the UK soon afterwards. The same people who are linked to those attempting to surreptitiously nudge your behaviour through suggestion or the threat of social indignation are also driving the agenda to create pharmaceuticals that induce biological behavioural changes, too. It is an assault on both the body and the mind simultaneously.

The world that the likes of Epstein, Junkermann, Angermayer, and Thiel have designed will benefit the wealthy few, not the impoverished masses. The only way they can create the society they desire is if we stop resisting their vision of an elitist and nepotistic meritocracy. Essentially, the subjugation of humanity relies on the majority of us taking pharmaceutical products, which condition us to be continuously psychologically manipulated. On top of this, we will be sold products which claim to enhance human physicality or psychology in a way which requires regular ongoing treatments.

Thiel and Angermayer’s Enhanced Games is a relatively overt effort to normalise Transhumanism. It will eventually happen in some way. UFC-style mixed martial arts was once taboo, partly because it broke lots of previously untested rivalries, but mostly because it allowed the best fighters to use everything in their physical arsenal to win. For many, the sport was too extreme.

Is the current iteration of the Olympic Games to the Enhanced Games, what Boxing was to the UFC? The UFC changed the rules of the game to test the boundaries of human endeavour, which is laudable to a degree. However, unenhanced natural human endeavour is still the pinnacle of achievement for the UFC. The UFC has the comprehensive Anti-Doping Program (UFC ADP), which is widely regarded as the strongest in professional sports. Still, Angermayer and Thiel’s Enhanced Games is not meant to be an alternative to the Olympic Games; it’s intended to replace them. The people in this investigation seek to replace human endeavour entirely with transhuman endeavour.

We should not be so naïve as to believe that humans won’t be interested in an Enhanced Games. It may start as a joke, but it will likely become genuine as enhanced athletes break official world records. Regardless of the ethics or morality of doping athletes, chemical enhancement often yields better results for those competing at the highest level; if it didn’t work, nobody would dope. Still, it is the normalisation of enhanced humans which is the real goal for the Transhumanist Elite. In their world, the evolution of sporting events starts with the Olympics, moves on to the Enhanced Games, and ends in mutant or cyber games. That may sound like science fiction, but that’s the issue the next generation will be faced with.

Transhumans are already all around us, and they aren’t just waiting for technology to catch up; they’re evangelising the required technology into existence. While we are distracted by the destruction of our current social order by these very people, they are using all available technologies to manipulate and change our behaviour in myriad ways. The stark reality is that the human population on Earth will change their behaviour when the appropriate prompt is applied.

The Transhumanists require the momentum to their brave new world to build into a critical mass. As Transhumanism becomes a reality, they need us to behave in such a way that we are willing to leave Humanity behind.

They need us to behave like we’re slaves. They need us to behave like we are cattle. They need us to BEHAVE!